Checkmate Pharmaceuticals, Inc.

CMPICIK 0001651431 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 29, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0000

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Checkmate Pharmaceuticals, Inc.

Name	Roles	Filings
Flaherty Keith T.	Director	1
Fuhrman Alan	Director	1
Isacoff Oren	Director	1
Novo Holdings A/S	10% Owner	1
Powell Michael	Director	1

Showing 11-15 of 16

Per pagePrevPage 3 of 4Next

All filings

23 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
May 31, 2022	Bash Alan Chief Executive Officer · Director	Holdings only	-	-	-
May 31, 2022	Fuhrman Alan Director	Holdings only	-	-	-
May 31, 2022	Wigginton Jon Marc Director	Holdings only	-	-	-
May 31, 2022	Wooldridge James Chief Medical Officer	Holdings only	-	-	-
May 31, 2022	Dolski Robert Chief Financial Officer	Holdings only	-	-	-

Showing 1-5 of 23

Per pagePage 1 of 5Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value